{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:49:33Z","timestamp":1792838973325,"version":"4.5.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40263-024-01126-8","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:02:08Z","timestamp":1728558128000},"page":"23-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-2857","authenticated-orcid":false,"given":"Ebony","family":"Quintrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofa","family":"Rahmannia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Wyrwoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Larcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kelty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"12","key":"1126_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry. 2018;5(12):987\u20131012. https:\/\/doi.org\/10.1016\/S2215-0366(18)30337-7.","journal-title":"The Lancet Psychiatry"},{"key":"1126_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01670-3","author":"EM Burnette","year":"2022","unstructured":"Burnette EM, Nieto SJ, Grodin EN, et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs. 2022. https:\/\/doi.org\/10.1007\/s40265-021-01670-3.","journal-title":"Drugs"},{"key":"1126_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agae063","author":"E Quintrell","year":"2024","unstructured":"Quintrell E, Page A, Wyrwoll C, et al. Alcohol pharmacotherapy dispensing trends in Australia between 2006 and 2023. Alcohol Alcohol. 2024;59(5).\u00a0https:\/\/doi.org\/10.1093\/alcalc\/agae063.","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"1126_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2125.2012.04452.x","volume":"76","author":"GK Hulse","year":"2013","unstructured":"Hulse GK. Improving clinical outcomes for naltrexone as a management of problem alcohol use. Br J Clin Pharmacol. 2013;76(5):632\u201341. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04452.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1126_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/ajo.12074","volume":"53","author":"SR Mallard","year":"2013","unstructured":"Mallard SR, Houghton LA. Socio-demographic characteristics associated with unplanned pregnancy in New Zealand: implications for access to preconception healthcare. Aust N Z J Obstet Gynaecol. 2013;53(5):498\u2013501. https:\/\/doi.org\/10.1111\/ajo.12074.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"1126_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2393-11-27","volume":"11","author":"A Mullally","year":"2011","unstructured":"Mullally A, Cleary BJ, Barry J, et al. Prevalence, predictors and perinatal outcomes of peri-conceptional alcohol exposure-retrospective cohort study in an urban obstetric population in Ireland. BMC Pregnancy Childbirth. 2011;11(1):1\u20137. https:\/\/doi.org\/10.1186\/1471-2393-11-27.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"1126_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12884-015-0663-4","volume":"15","author":"E Oulman","year":"2015","unstructured":"Oulman E, Kim THM, Yunis K, et al. Prevalence and predictors of unintended pregnancy among women: an analysis of the Canadian Maternity Experiences Survey. BMC Pregnancy Childbirth. 2015;15(1):1\u20138. https:\/\/doi.org\/10.1186\/s12884-015-0663-4.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"10","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/jpc.13625","volume":"53","author":"C Bower","year":"2017","unstructured":"Bower C, Elliott EJ, Zimmet M, et al. Australian guide to the diagnosis of foetal alcohol spectrum disorder: a summary. J Paediatr Child Health. 2017;53(10):1021. https:\/\/doi.org\/10.1111\/jpc.13625.","journal-title":"J Paediatr Child Health"},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.drugalcdep.2019.01.007","volume":"197","author":"KE Easey","year":"2019","unstructured":"Easey KE, Dyer ML, Timpson NJ, et al. Prenatal alcohol exposure and offspring mental health: A systematic review. Drug Alcohol Depend. 2019;197:344\u201353. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.01.007.","journal-title":"Drug Alcohol Depend"},{"key":"1126_CR10","volume-title":"Guidelines for the identification and management of substance abuse and substance use disorders in pregnancy","author":"World Health Organization (WHO)","year":"2014","unstructured":"World Health Organization (WHO). Guidelines for the identification and management of substance abuse and substance use disorders in pregnancy. Geneva: WHO Press; 2014."},{"issue":"7","key":"1126_CR11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269881112444324","volume":"26","author":"AR Lingford-Hughes","year":"2012","unstructured":"Lingford-Hughes AR, Welch S, Peters L, et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899\u2013952. https:\/\/doi.org\/10.1177\/0269881112444324.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/cns.12489","volume":"22","author":"B Rolland","year":"2016","unstructured":"Rolland B, Paille F, Gillet C, et al. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22(1):25\u201337. https:\/\/doi.org\/10.1111\/cns.12489.","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"1126_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15622975.2018.1510185","volume":"20","author":"F Thibaut","year":"2019","unstructured":"Thibaut F, Chagraoui A, Buckley L, et al. WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. World J Biol Psychiatry. 2019;20(1):17\u201350. https:\/\/doi.org\/10.1080\/15622975.2018.1510185.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"1126_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","volume":"175","author":"VI Reus","year":"2018","unstructured":"Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86\u201390. https:\/\/doi.org\/10.1176\/appi.ajp.2017.1750101.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"1126_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"key":"1126_CR16","unstructured":"Quintrell E, and Kelty, E. Are alcohol pharmacotherapies safe for use in pregnancy? Open Science Framework; 2022. 10.17605\/OSF.IO\/B2E39."},{"key":"1126_CR17","unstructured":"EndNote. EndNote 20 EndNote X9 ed. Philadelphia, PA: Clarivate; 2013."},{"key":"1126_CR18","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org. Accessed 31 Aug 2022."},{"issue":"5","key":"1126_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.0004-8666.2002.548_14.x","volume":"42","author":"G Hulse","year":"2002","unstructured":"Hulse G, O\u2019Neil GK. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol. 2002;42(5):569\u201373. https:\/\/doi.org\/10.1111\/j.0004-8666.2002.548_14.x.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"2","key":"1126_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijgo.2003.10.001","volume":"85","author":"GK Hulse","year":"2004","unstructured":"Hulse GK, O\u2019Neil G, Arnold-Reed D. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. IntJ Gynecol Obstet. 2004;85(2):170\u20131. https:\/\/doi.org\/10.1016\/j.ijgo.2003.10.001.","journal-title":"IntJ Gynecol Obstet"},{"issue":"4","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1479-828X.2001.tb01322.x","volume":"41","author":"GK Hulse","year":"2001","unstructured":"Hulse GK, O\u2019Neill G, Pereira C, et al. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol. 2001;41(4):424\u20138. https:\/\/doi.org\/10.1111\/j.1479-828X.2001.tb01322.x.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"11","key":"1126_CR22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s40265-017-0762-9","volume":"77","author":"E Kelty","year":"2017","unstructured":"Kelty E, Hulse G. A retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls. Drugs. 2017;77(11):1199\u2013210. https:\/\/doi.org\/10.1007\/s40265-017-0762-9.","journal-title":"Drugs"},{"issue":"11","key":"1126_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40265-017-0763-8","volume":"77","author":"E Kelty","year":"2017","unstructured":"Kelty E, Hulse G. A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine-and non-opioid-exposed neonates. Drugs. 2017;77(11):1211\u20139. https:\/\/doi.org\/10.1007\/s40265-017-0763-8.","journal-title":"Drugs"},{"issue":"8","key":"1126_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/ajad.12642","volume":"26","author":"E Kelty","year":"2017","unstructured":"Kelty E, Hulse G. A retrospective cohort study of the health of children prenatally exposed to methadone, buprenorphine or naltrexone compared with non-exposed control children. Am J Addict. 2017;26(8):845\u201351. https:\/\/doi.org\/10.1111\/ajad.12642.","journal-title":"Am J Addict"},{"issue":"1","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"83.e1","DOI":"10.1016\/j.ajog.2019.07.037","volume":"222","author":"CV Towers","year":"2020","unstructured":"Towers CV, Katz E, Weitz B, et al. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020;222(1):83.e1-83.e8. https:\/\/doi.org\/10.1016\/j.ajog.2019.07.037.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.clinthera.2019.07.003","volume":"41","author":"EM Wachman","year":"2019","unstructured":"Wachman EM, Saia K, Miller M, et al. Naltrexone treatment for pregnant women with opioid use disorder compared with matched buprenorphine control subjects. Clin Ther. 2019;41(9):1681\u20139. https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.003.","journal-title":"Clin Ther"},{"issue":"5","key":"1126_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/AOG.0000000000002562","volume":"131","author":"M Terplan","year":"2018","unstructured":"Terplan M, Laird HJ, Hand DJ, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;131(5):803\u201314. https:\/\/doi.org\/10.1097\/AOG.0000000000002562.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1126_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4025\/actascibiolsci.v33i2.5940","volume":"33","author":"FM Caj\u00fa","year":"2011","unstructured":"Caj\u00fa FM, Queiroz GCDA, Torres SM, et al. Opioid system manipulation during testicular development: results on sperm production and sertoli cells population. Acta scientiarum. Biol Sci. 2011;33(2):219\u201325. https:\/\/doi.org\/10.4025\/actascibiolsci.v33i2.5940.","journal-title":"Biol Sci"},{"issue":"1","key":"1126_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0091-3057(95)02160-4","volume":"54","author":"E Cohen","year":"1996","unstructured":"Cohen E, Keshet G, Shavit Y, et al. Prenatal naltrexone facilitates male sexual behavior in the rat. Pharmacol Biochem Behav. 1996;54(1):183\u20138. https:\/\/doi.org\/10.1016\/0091-3057(95)02160-4.","journal-title":"Pharmacol Biochem Behav"},{"issue":"12","key":"1126_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052812","volume":"7","author":"WO Farid","year":"2012","unstructured":"Farid WO, Lawrence AJ, Krstew EV, et al. Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood. PLoS ONE. 2012;7(12): e52812. https:\/\/doi.org\/10.1371\/journal.pone.0052812.","journal-title":"PLoS ONE"},{"issue":"4","key":"1126_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0093-691X(00)00239-9","volume":"53","author":"C Gilbert","year":"2000","unstructured":"Gilbert C, Boulton M, Goode J, et al. The timing of parturition in the pig is altered by intravenous naloxone. Theriogenology. 2000;53(4):905\u201323. https:\/\/doi.org\/10.1016\/S0093-691X(00)00239-9.","journal-title":"Theriogenology"},{"issue":"2","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejogrb.2009.08.014","volume":"147","author":"M Javadi-Paydar","year":"2009","unstructured":"Javadi-Paydar M, Lesani A, Vakilipour R, et al. Evaluation of the tocolytic effect of morphine in a mouse model of lipopolysaccharide-induced preterm delivery: the role of nitric oxide. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):166\u201372. https:\/\/doi.org\/10.1016\/j.ejogrb.2009.08.014.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"1126_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0091-3057(94)00289-U","volume":"50","author":"GI Keshet","year":"1995","unstructured":"Keshet GI, Weinstock M. Maternal naltrexone prevents morphological and behavioral alterations induced in rats by prenatal stress. Pharmacol Biochem Behav. 1995;50(3):413\u20139. https:\/\/doi.org\/10.1016\/0091-3057(94)00289-U.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"1126_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000063611","volume":"82","author":"PJ McLaughlin","year":"2002","unstructured":"McLaughlin PJ. Exposure to the opioid antagonist naltrexone throughout gestation alters postnatal heart development. Neonatology. 2002;82(3):207\u201316. https:\/\/doi.org\/10.1159\/000063611.","journal-title":"Neonatology"},{"issue":"3","key":"1126_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0031-9384(97)00007-3","volume":"62","author":"PJ McLaughlin","year":"1997","unstructured":"McLaughlin PJ, Tobias SW, Lang CM, et al. Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects. Physiol Behav. 1997;62(3):501\u20138. https:\/\/doi.org\/10.1016\/S0031-9384(97)00007-3.","journal-title":"Physiol Behav"},{"issue":"4","key":"1126_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0091-3057(97)00307-9","volume":"58","author":"PJ McLaughlin","year":"1997","unstructured":"McLaughlin PJ, Tobias SW, Lang CM, et al. Opioid receptor blockade during prenatal life modifies postnatal behavioral development. Pharmacol Biochem Behav. 1997;58(4):1075\u201382. https:\/\/doi.org\/10.1016\/S0091-3057(97)00307-9.","journal-title":"Pharmacol Biochem Behav"},{"key":"1126_CR37","unstructured":"Medina Jimenez M, LEM., Rodriguez R. Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice. Arch Med Res. 1997;28(1): p. 61\u201365."},{"issue":"5\u20136","key":"1126_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/0361-9230(93)90078-P","volume":"30","author":"JV Seatriz","year":"1993","unstructured":"Seatriz JV, Hammer RP Jr. Effects of opiates on neuronal development in the rat cerebral cortex. Brain Res Bull. 1993;30(5\u20136):523\u20137. https:\/\/doi.org\/10.1016\/0361-9230(93)90078-P.","journal-title":"Brain Res Bull"},{"issue":"10","key":"1126_CR39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1258\/ebm.2012.012132","volume":"237","author":"SL Youngentob","year":"2012","unstructured":"Youngentob SL, Kent PF, Youngentob LM. Gestational naltrexone ameliorates fetal ethanol exposures enhancing effect on the postnatal behavioral and neural response to ethanol. Exp Biol Med. 2012;237(10):1197\u2013208. https:\/\/doi.org\/10.1258\/ebm.2012.012132.","journal-title":"Exp Biol Med"},{"issue":"1","key":"1126_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0091-3057(97)00419-X","volume":"59","author":"IS Zagon","year":"1998","unstructured":"Zagon IS, Tobias SW, Hytrek SD, et al. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters \u03bc opioid receptors. Pharmacol Biochem Behav. 1998;59(1):201\u20137. https:\/\/doi.org\/10.1016\/S0091-3057(97)00419-X.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"1126_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2004.10.037","volume":"374","author":"C Adde-Michel","year":"2005","unstructured":"Adde-Michel C, Hennebert O, Laudenbach V, et al. Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamsters. Neurosci Lett. 2005;374(2):109\u201312.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1126_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/add.14429","volume":"114","author":"E Kelty","year":"2019","unstructured":"Kelty E, Tran D, Lavin T, et al. Prevalence and safety of acamprosate use in pregnant alcohol-dependent women in New South Wales, Australia. Addiction. 2019;114(2):206\u201315. https:\/\/doi.org\/10.1111\/add.14429.","journal-title":"Addiction"},{"key":"1126_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2022.114037","volume":"259","author":"E Quintrell","year":"2023","unstructured":"Quintrell E, Wyrwoll C, Rosenow T, et al. The effects of acamprosate on maternal and neonatal outcomes in a mouse model of alcohol use disorders. Physiol Behav. 2023;259: 114037. https:\/\/doi.org\/10.1016\/j.physbeh.2022.114037.","journal-title":"Physiol Behav"},{"key":"1126_CR44","volume-title":"Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk","author":"GF Briggs","year":"2017","unstructured":"Briggs GF, Towers RK, Craig V, Forinash, Alicia B. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Eleventh. Lippincott Williams & Wilkins; 2017.","edition":"Eleventh"},{"issue":"22","key":"1126_CR45","first-page":"1394","volume":"13","author":"P Dehaene","year":"1984","unstructured":"Dehaene P, Titran M, Dubois D. Pierre Robin syndrome and heart malformations in a newborn infant. The role of disulfiram during pregnancy? Presse Med. 1984;13(22):1394\u20135.","journal-title":"Presse Med"},{"issue":"680","key":"1126_CR46","first-page":"184","volume":"93","author":"R Gardner","year":"1981","unstructured":"Gardner R, Clarkson J. A malformed child whose previously alcoholic mother had taken disulfiram. N Z Med J. 1981;93(680):184\u20136.","journal-title":"N Z Med J"},{"issue":"8039","key":"1126_CR47","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S0140-6736(77)92534-X","volume":"310","author":"AH Nora","year":"1977","unstructured":"Nora AH, Nora JJ, Blu J. Limb-reduction anomalies in infants born to disulfiram-treated alcoholic mothers. The Lancet. 1977;310(8039):664. https:\/\/doi.org\/10.1016\/S0140-6736(77)92534-X.","journal-title":"The Lancet"},{"issue":"3","key":"1126_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1741-4520.1993.tb00526.x","volume":"33","author":"AJ Harding","year":"1993","unstructured":"Harding AJ, Edwards MJ. Retardation of prenatal brain growth of guinea pigs by disulfiram. Congenit Anom. 1993;33(3):197\u2013202. https:\/\/doi.org\/10.1111\/j.1741-4520.1993.tb00526.x.","journal-title":"Congenit Anom"},{"issue":"9","key":"1126_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/bdra.20385","volume":"79","author":"CS Johnson","year":"2007","unstructured":"Johnson CS, Zucker RM, Hunter IES, et al. Perturbation of retinoic acid (RA)-mediated limb development suggests a role for diminished RA signaling in the teratogenesis of ethanol. Birth Defects Res Part A Clin Mol Teratol. 2007;79(9):631\u201341. https:\/\/doi.org\/10.1002\/bdra.20385.","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"issue":"3","key":"1126_CR50","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/ijms24032371","volume":"24","author":"M Teng","year":"2023","unstructured":"Teng M, Luo Y, Wang C, et al. Effect of disulfiram on the reproductive capacity of female mice. Int J Mol Sci. 2023;24(3):2371. https:\/\/doi.org\/10.3390\/ijms24032371.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1126_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.pmrj.2009.07.010","volume":"1","author":"CM Morton","year":"2009","unstructured":"Morton CM, Rosenow J, Wong C, et al. Intrathecal baclofen administration during pregnancy: a case series and focused clinical review. PM&R. 2009;1(11):1025\u20139. https:\/\/doi.org\/10.1016\/j.pmrj.2009.07.010.","journal-title":"PM&R"},{"key":"1126_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12434","author":"P Gomora-Arrati","year":"2016","unstructured":"Gomora-Arrati P, Dominguez G, Agmo A. GABA receptors in the medial preoptic area modulate the onset of oestradiol-induced maternal behaviour in hysterectomised-ovariectomised, pregnant rats. J Neuroendocrinol. 2016. https:\/\/doi.org\/10.1111\/jne.12434.","journal-title":"J Neuroendocrinol"},{"key":"1126_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2210-1-2","volume":"1","author":"W Briner","year":"2001","unstructured":"Briner W. The effect of GABA receptor ligands in experimental spina bifida occulta. BMC Pharmacol. 2001;1:2. https:\/\/doi.org\/10.1186\/1471-2210-1-2.","journal-title":"BMC Pharmacol"},{"issue":"9","key":"1126_CR54","first-page":"639","volume":"24","author":"W Briner","year":"1996","unstructured":"Briner W. Muscimol- and baclofen-induced spina bifida in the rat. Med Sci Res. 1996;24(9):639\u201340.","journal-title":"Med Sci Res"},{"key":"1126_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26561","author":"JM Cohen","year":"2023","unstructured":"Cohen JM, Alvestad S, Cesta CE, et al. Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations. Ann Neurol. 2023. https:\/\/doi.org\/10.1002\/ana.26561.","journal-title":"Ann Neurol"},{"issue":"4","key":"1126_CR56","doi-asserted-by":"publisher","first-page":"E342","DOI":"10.1212\/WNL.0000000000004857","volume":"90","author":"S Hernandez-Diaz","year":"2018","unstructured":"Hernandez-Diaz S, Huybrechts KF, Desai RJ, et al. Topiramate use early in pregnancy and the risk of oral clefts A pregnancy cohort study. Neurology. 2018;90(4):E342\u201351. https:\/\/doi.org\/10.1212\/WNL.0000000000004857.","journal-title":"Neurology"},{"issue":"21","key":"1126_CR57","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","volume":"78","author":"S Hernandez-Diaz","year":"2012","unstructured":"Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e3182574f39.","journal-title":"Neurology"},{"issue":"4","key":"1126_CR58","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","volume":"71","author":"S Hunt","year":"2008","unstructured":"Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology. 2008;71(4):272\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000318293.28278.33.","journal-title":"Neurology"},{"key":"1126_CR59","doi-asserted-by":"publisher","first-page":"106250","DOI":"10.1016\/j.eplepsyres.2019.106250","volume":"159","author":"RR Keni","year":"2020","unstructured":"Keni RR, Jose M, Reshma AS, et al. Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. Epilepsy Res. 2020;159:106250. https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106250.","journal-title":"Epilepsy Res"},{"key":"1126_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.seizure.2023.01.008","volume":"105","author":"R Knight","year":"2023","unstructured":"Knight R, Craig J, Irwin B, et al. Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study. Seizure. 2023;105:56\u201364. https:\/\/doi.org\/10.1016\/j.seizure.2023.01.008.","journal-title":"Seizure"},{"issue":"2","key":"1126_CR61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/pds.5568","volume":"32","author":"JG Lyons","year":"2023","unstructured":"Lyons JG, Suarez EA, Fazio-Eynullayeva E, et al. Assessing medical product safety during pregnancy using parameterizable tools in the sentinel distributed database. Pharmacoepidemiol Drug Saf. 2023;32(2):158\u2013215. https:\/\/doi.org\/10.1002\/pds.5568.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1126_CR62","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/pds.3612","volume":"23","author":"D Mines","year":"2014","unstructured":"Mines D, Tennis P, Curkendall SM, et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014;23(10):1017\u201325. https:\/\/doi.org\/10.1002\/pds.3612.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1126_CR63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/bdra.23357","volume":"103","author":"P Tennis","year":"2015","unstructured":"Tennis P, Chan KA, Curkendall SM, et al. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res Part A Clin Mol Teratol. 2015;103(4):269\u201375. https:\/\/doi.org\/10.1002\/bdra.23357.","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"key":"1126_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109219","volume":"142","author":"F Vajda","year":"2023","unstructured":"Vajda F, O\u2019Brien T, Graham J, et al. Specific fetal malformations following intrauterine exposure to antiseizure medication. Epilepsy Behav. 2023;142: 109219. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109219.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1126_CR65","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ane.12115","volume":"128","author":"FJE Vajda","year":"2013","unstructured":"Vajda FJE, O\u2019Brien TJ, Graham J, et al. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand. 2013;128(4):228\u201334. https:\/\/doi.org\/10.1111\/ane.12115.","journal-title":"Acta Neurol Scand"},{"key":"1126_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106481","volume":"103","author":"FJE Vajda","year":"2020","unstructured":"Vajda FJE, O\u2019Brien TJ, Graham JE, et al. Preexisting illness, fetal malformation, and seizure control rates in pregnant women with epilepsy. Epilepsy Behav. 2020;103: 106481. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106481.","journal-title":"Epilepsy Behav"},{"key":"1126_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107941","volume":"118","author":"FJE Vajda","year":"2021","unstructured":"Vajda FJE, O\u2019Brien TJ, Graham JE, et al. The contribution of non-drug factors to fetal malformation in anti-seizure-medication-treated pregnancy. Epilepsy Behav. 2021;118: 107941. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107941.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1126_CR68","doi-asserted-by":"publisher","first-page":"E167","DOI":"10.1212\/WNL.0000000000007696","volume":"93","author":"PO Blotiere","year":"2019","unstructured":"Blotiere PO, Raguideau F, Weill A, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019;93(2):E167\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000007696.","journal-title":"Neurology"},{"issue":"18","key":"1126_CR69","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/bdr2.1789","volume":"112","author":"SM Kerr","year":"2020","unstructured":"Kerr SM, Parker SE, Mitchell AA, et al. Folic acid antagonist use before and during pregnancy and risk for selected birth defects. Birth Defects Res. 2020;112(18):1526\u201340. https:\/\/doi.org\/10.1002\/bdr2.1789.","journal-title":"Birth Defects Res"},{"issue":"5","key":"1126_CR70","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2012.07.008","volume":"207","author":"AV Margulis","year":"2012","unstructured":"Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):e1-405. https:\/\/doi.org\/10.1016\/j.ajog.2012.07.008.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1126_CR71","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1526-4610.2012.02190.x","volume":"52","author":"MW Green","year":"2012","unstructured":"Green MW, Seeger JD, Peterson C, et al. Utilization of topiramate during pregnancy and risk of birth defects. Headache. 2012;52(7):1070\u201384. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02190.x.","journal-title":"Headache"},{"issue":"9","key":"1126_CR72","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/OGX.0b013e31823b6211","volume":"66","author":"D Molgaard-Nielsen","year":"2011","unstructured":"Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. Obstet Gynecol Surv. 2011;66(9):543\u20134. https:\/\/doi.org\/10.1097\/OGX.0b013e31823b6211.","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"1126_CR73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","volume":"77","author":"J Morrow","year":"2006","unstructured":"Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193\u20138. https:\/\/doi.org\/10.1136\/jnnp.2005.074203.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1126_CR74","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.reprotox.2008.03.001","volume":"25","author":"A Ornoy","year":"2008","unstructured":"Ornoy A, Zvi N, Arnon J, et al. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol. 2008;25(3):388\u20139. https:\/\/doi.org\/10.1016\/j.reprotox.2008.03.001.","journal-title":"Reprod Toxicol"},{"issue":"6","key":"1126_CR75","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","volume":"17","author":"T Tomson","year":"2018","unstructured":"Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. The Lancet Neurology. 2018;17(6):530\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(18)30107-8.","journal-title":"The Lancet Neurology"},{"issue":"1","key":"1126_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jocn.2011.08.003","volume":"19","author":"FJE Vajda","year":"2012","unstructured":"Vajda FJE, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs\u2013the Australian experience. J Clin Neurosci. 2012;19(1):57\u20139. https:\/\/doi.org\/10.1016\/j.jocn.2011.08.003.","journal-title":"J Clin Neurosci"},{"key":"1126_CR77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.seizure.2018.12.006","volume":"65","author":"FJE Vajda","year":"2019","unstructured":"Vajda FJE, Graham JE, Hitchcock AA, et al. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure. 2019;65:6\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2018.12.006.","journal-title":"Seizure"},{"issue":"5","key":"1126_CR78","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1528-1167.2009.02336.x","volume":"51","author":"FJE Vajda","year":"2010","unstructured":"Vajda FJE, Hitchcock AA, Graham J, et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia. 2010;51(5):805\u201310. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02336.x.","journal-title":"Epilepsia"},{"issue":"1","key":"1126_CR79","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1479-828X.2011.01359.x","volume":"52","author":"FJE Vajda","year":"2012","unstructured":"Vajda FJE, Horgan D, Hollingworth S, et al. The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol. 2012;52(1):49\u201353. https:\/\/doi.org\/10.1111\/j.1479-828X.2011.01359.x.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"2","key":"1126_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/ane.12965","volume":"138","author":"FJE Vajda","year":"2018","unstructured":"Vajda FJE, O\u2019Brien TJ, Graham JE, et al. Antiepileptic drug polytherapy in pregnant women with epilepsy. Acta Neurol Scand. 2018;138(2):115\u201321. https:\/\/doi.org\/10.1111\/ane.12965.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1126_CR81","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/ane.12280","volume":"130","author":"FJE Vajda","year":"2014","unstructured":"Vajda FJE, O\u2019Brien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs - An update. Acta Neurol Scand. 2014;130(4):234\u20138. https:\/\/doi.org\/10.1111\/ane.12280.","journal-title":"Acta Neurol Scand"},{"key":"1126_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13415","author":"FJE Vajda","year":"2016","unstructured":"Vajda FJE, O\u2019Brien TJ, Lander CM, et al. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia. 2016. https:\/\/doi.org\/10.1111\/epi.13415.","journal-title":"Epilepsia"},{"issue":"3","key":"1126_CR83","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00415-013-7239-x","volume":"261","author":"G Veiby","year":"2014","unstructured":"Veiby G, Daltveit AK, Engelsen BA, et al. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579\u201388. https:\/\/doi.org\/10.1007\/s00415-013-7239-x.","journal-title":"J Neurol"},{"issue":"3","key":"1126_CR84","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1528-1167.2008.01776.x","volume":"50","author":"AA Westin","year":"2009","unstructured":"Westin AA, Nakken KO, Johannessen SI, et al. Serum concentration\/dose ratio of topiramate during pregnancy. Epilepsia. 2009;50(3):480\u20135. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01776.x.","journal-title":"Epilepsia"},{"issue":"4","key":"1126_CR85","doi-asserted-by":"publisher","first-page":"18m12572","DOI":"10.4088\/JCP.18m12572","volume":"80","author":"JM Cohen","year":"2019","unstructured":"Cohen JM, Huybrechts KF, Patorno E, et al. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psychiatry. 2019;80(4):18m12572. https:\/\/doi.org\/10.4088\/JCP.18m12572.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1126_CR86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.25031","volume":"82","author":"S Hernandez-Diaz","year":"2017","unstructured":"Hernandez-Diaz S, McElrath TF, Pennell PB, et al. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol. 2017;82(3):457\u201365. https:\/\/doi.org\/10.1002\/ana.25031.","journal-title":"Ann Neurol"},{"issue":"1","key":"1126_CR87","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/AOG.0000000000000018","volume":"123","author":"S Hernandez-Diaz","year":"2014","unstructured":"Hernandez-Diaz S, Mittendorf R, Smith CR, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014;123(1):21\u20138. https:\/\/doi.org\/10.1097\/AOG.0000000000000018.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"1126_CR88","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/epi.12758","volume":"55","author":"D Kilic","year":"2014","unstructured":"Kilic D, Pedersen H, Kjaersgaard MIS, et al. Birth outcomes after prenatal exposure to antiepileptic drugs - A population-based study. Epilepsia. 2014;55(11):1714\u201321. https:\/\/doi.org\/10.1111\/epi.12758.","journal-title":"Epilepsia"},{"key":"1126_CR89","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eplepsyres.2018.07.016","volume":"146","author":"M Trivedi","year":"2018","unstructured":"Trivedi M, Jose M, Philip RM, et al. Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Res. 2018;146:50\u20133. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.07.016.","journal-title":"Epilepsy Res"},{"key":"1126_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2023.109953","volume":"120","author":"A Sarayani","year":"2023","unstructured":"Sarayani A, Winterstein A, Cristofoletti R, et al. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes. Contraception. 2023;120: 109953. https:\/\/doi.org\/10.1016\/j.contraception.2023.109953.","journal-title":"Contraception"},{"issue":"1","key":"1126_CR91","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ane.12816","volume":"137","author":"FJE Vajda","year":"2018","unstructured":"Vajda FJE, O\u2019Brien TJ, Graham J, et al. Anti-epileptic drug exposure and risk of foetal death in utero. Acta Neurol Scand. 2018;137(1):20\u20133. https:\/\/doi.org\/10.1111\/ane.12816.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"1126_CR92","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.reprotox.2012.05.038","volume":"34","author":"T Rihtman","year":"2012","unstructured":"Rihtman T, Parush S, Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol. 2012;34(3):308\u201311. https:\/\/doi.org\/10.1016\/j.reprotox.2012.05.038.","journal-title":"Reprod Toxicol"},{"issue":"7","key":"1126_CR93","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jamaneurol.2022.1269","volume":"79","author":"MH Bjork","year":"2022","unstructured":"Bjork MH, Zoega H, Leinonen MK, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79(7):772\u201381. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1269.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1126_CR94","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","volume":"89","author":"LF Bech","year":"2018","unstructured":"Bech LF, Polcwiartek C, Kragholm K, et al. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry. 2018;89(12):1324\u201331. https:\/\/doi.org\/10.1136\/jnnp-2018-318386.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1126_CR95","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jamaneurol.2023.0674","volume":"80","author":"JW Dreier","year":"2023","unstructured":"Dreier JW, Bjork MH, Alvestad S, et al. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurol. 2023;80(6):568\u201377. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0674.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1126_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034829","volume":"10","author":"PO Blotiere","year":"2020","unstructured":"Blotiere PO, Miranda S, Weill A, et al. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open. 2020;10(6): e034829. https:\/\/doi.org\/10.1136\/bmjopen-2019-034829.","journal-title":"BMJ Open"},{"issue":"1","key":"1126_CR97","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1038\/s41598-020-74409-x","volume":"10","author":"J Coste","year":"2020","unstructured":"Coste J, Blotiere P-O, Miranda S, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep. 2020;10(1):17362. https:\/\/doi.org\/10.1038\/s41598-020-74409-x.","journal-title":"Sci Rep"},{"issue":"18","key":"1126_CR98","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","volume":"87","author":"RL Bromley","year":"2016","unstructured":"Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;87(18):1943\u201353. https:\/\/doi.org\/10.1212\/WNL.0000000000003157.","journal-title":"Neurology"},{"key":"1126_CR99","unstructured":"Mishra A, Singh M. Topiramate induced histopathological changes in placenta of rats. Indian J. Exp. Biol., 2008;46(10):715-719."},{"issue":"5","key":"1126_CR100","first-page":"195","volume":"32","author":"M Singh","year":"2009","unstructured":"Singh M, Mishra A. Topiramate induced congenital malformations in rats. Natl Acad Sci Lett. 2009;32(5):195.","journal-title":"Natl Acad Sci Lett"},{"issue":"2","key":"1126_CR101","first-page":"321","volume":"53","author":"R Fadel","year":"2012","unstructured":"Fadel R, Sequeira R, Abu-Hijleh M, et al. Effect of prenatal administration of therapeutic doses of topiramate on ossification of ribs and vertebrae in rat fetuses. Rom J Morphol Embryol. 2012;53(2):321\u20137.","journal-title":"Rom J Morphol Embryol"},{"issue":"5880","key":"1126_CR102","doi-asserted-by":"publisher","first-page":"214","DOI":"10.12816\/0047509","volume":"158","author":"R Fadel","year":"2016","unstructured":"Fadel R, Skrypnyk C, Salem AH, et al. Effects of topiramate on pregnancy outcome in rats. Bahrain Med Bull. 2016;158(5880):214-218.","journal-title":"Bahrain Med Bull"},{"issue":"3","key":"1126_CR103","first-page":"245","volume":"45","author":"FT Abdul-Rhahman","year":"2011","unstructured":"Abdul-Rhahman FT, Al-Allaf LI, Al-Nuaimy HA. The histological changes of albino mice embryos\u2019 kidneys after exposure in utero to topiramate. Jordan Med J. 2011;45(3):245\u201354.","journal-title":"Jordan Med. J."},{"issue":"2","key":"1126_CR104","doi-asserted-by":"publisher","first-page":"90","DOI":"10.12816\/0047603","volume":"38","author":"R Fadel","year":"2016","unstructured":"Fadel R, Othman M, Abu-Hijleh M, et al. Effects of topiramate administration on placenta of rat. Bahrain Med Bull. 2016;38(2):90\u20133.","journal-title":"Bahrain Med Bull"},{"issue":"3","key":"1126_CR105","doi-asserted-by":"publisher","first-page":"54","DOI":"10.22159\/ijpps.2017v9i3.16208","volume":"9","author":"EY Salah El-Din","year":"2017","unstructured":"Salah El-Din EY, Omar AR. Effect of prenatal administration of therapeutic dose of topiramate on placentae albino rats\u2019 fetuses. Int J Pharm Pharm Sci. 2017;9(3):54\u20139. https:\/\/doi.org\/10.22159\/ijpps.2017v9i3.16208.","journal-title":"Int J Pharm Pharm Sci"},{"issue":"8","key":"1126_CR106","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/ijms18081721","volume":"18","author":"Y-H Lai","year":"2017","unstructured":"Lai Y-H, Ding Y-J, Moses D, et al. Teratogenic effects of topiramate in a zebrafish model. Int J Mol Sci. 2017;18(8):1721. https:\/\/doi.org\/10.3390\/ijms18081721.","journal-title":"Int J Mol Sci"},{"key":"1126_CR107","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/726478","volume":"2013","author":"SH Lee","year":"2013","unstructured":"Lee SH, Kang JW, Lin T, et al. Teratogenic potential of antiepileptic drugs in the zebrafish model. Biomed Res Int. 2013;2013: 726478. https:\/\/doi.org\/10.1155\/2013\/726478.","journal-title":"Biomed Res Int"},{"issue":"2\u20133","key":"1126_CR108","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eplepsyres.2007.10.014","volume":"78","author":"J-B Manent","year":"2008","unstructured":"Manent J-B, Jorquera I, Franco V, et al. Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res. 2008;78(2\u20133):131\u20139. https:\/\/doi.org\/10.1016\/j.eplepsyres.2007.10.014.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1126_CR109","doi-asserted-by":"publisher","first-page":"691","DOI":"10.17219\/acem\/37219","volume":"23","author":"E Dag","year":"2014","unstructured":"Dag E, Dag ZO, Baydas G, et al. Effects of lamotrigine and topiramate on brain maturation and cognitive functions in offspring of pregnant rats\u2014preliminary study. Adv Clin Exp Med. 2014;23(5):691\u20138. https:\/\/doi.org\/10.17219\/acem\/37219.","journal-title":"Adv Clin Exp Med"},{"issue":"9","key":"1126_CR110","doi-asserted-by":"publisher","first-page":"1003322","DOI":"10.1371\/journal.pmed.1003322","volume":"17","author":"E Patorno","year":"2020","unstructured":"Patorno E, Hernandez-Diaz S, Huybrechts KF, et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US medicaid analytic eXtract dataset. PLoS Med. 2020;17(9):1003322. https:\/\/doi.org\/10.1371\/journal.pmed.1003322.","journal-title":"PLoS Med"},{"issue":"17","key":"1126_CR111","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1212\/WNL.0b013e31828f18c1","volume":"80","author":"H Fujii","year":"2013","unstructured":"Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565\u201370. https:\/\/doi.org\/10.1212\/WNL.0b013e31828f18c1.","journal-title":"Neurology"},{"issue":"2","key":"1126_CR112","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp-2017-316143","volume":"89","author":"B Mostacci","year":"2018","unstructured":"Mostacci B, Poluzzi E, D\u2019Alessandro R, et al. Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: Data from a population-based study. J Neurol Neurosurg Psychiatry. 2018;89(2):222\u20133. https:\/\/doi.org\/10.1136\/jnnp-2017-316143.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1126_CR113","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.seizure.2009.09.002","volume":"18","author":"M Almgren","year":"2009","unstructured":"Almgren M, Kallen B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero-Influence on head circumference in newborns. Seizure. 2009;18(10):672\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2009.09.002.","journal-title":"Seizure"},{"issue":"3","key":"1126_CR114","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/s1525-5050(03)00110-0","volume":"4","author":"G Montouris","year":"2003","unstructured":"Montouris G. Gabapentin exposure in human pregnancy: results from the gabapentin pregnancy registry. Epilepsy Behav. 2003;4(3):310\u20137. https:\/\/doi.org\/10.1016\/s1525-5050(03)00110-0.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1126_CR115","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/08035250310021118","volume":"93","author":"K Wide","year":"2004","unstructured":"Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica Int J Paediatrics. 2004;93(2):174\u20136. https:\/\/doi.org\/10.1080\/08035250310021118.","journal-title":"Acta Paediatrica Int J Paediatrics"},{"key":"1126_CR116","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jpeds.2020.10.030","volume":"229","author":"SW Patrick","year":"2021","unstructured":"Patrick SW, Slaughter JC, Harrell FE, et al. Development and validation of a model to predict neonatal abstinence syndrome. J Pediatr. 2021;229:154-160.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2020.10.030.","journal-title":"J Pediatr"},{"key":"1126_CR117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.drugalcdep.2018.07.024","volume":"192","author":"EM Wachman","year":"2018","unstructured":"Wachman EM, Warden AH, Thomas Z, et al. Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. Drug Alcohol Depend. 2018;192:45\u201350. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.024.","journal-title":"Drug Alcohol Depend"},{"key":"1126_CR118","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3326","volume":"358","author":"KF Huybrechts","year":"2017","unstructured":"Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: Cohort study. BMJ (Online). 2017;358: j3326. https:\/\/doi.org\/10.1136\/bmj.j3326.","journal-title":"BMJ (Online)"},{"key":"1126_CR119","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jpeds.2016.11.004","volume":"181","author":"S Loudin","year":"2017","unstructured":"Loudin S, Murray S, Prunty L, et al. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr. 2017;181:286\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2016.11.004.","journal-title":"J Pediatr"},{"issue":"4","key":"1126_CR120","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1006\/faat.1994.1144","volume":"23","author":"J Petrere","year":"1994","unstructured":"Petrere J, Anderson JA. Developmental toxicity studies in mice, rats, and rabbits with the anticonvulsant gabapentin. Fundam Appl Toxicol. 1994;23(4):585\u20139. https:\/\/doi.org\/10.1006\/faat.1994.1144.","journal-title":"Fundam Appl Toxicol"},{"issue":"3","key":"1126_CR121","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/14767058.2017.1383378","volume":"32","author":"Z Erisgin","year":"2019","unstructured":"Erisgin Z, Ayas B, Nyengaard JR, et al. The neurotoxic effects of prenatal gabapentin and oxcarbazepine exposure on newborn rats. J Maternal-Fetal Neonatal Med. 2019;32(3):461\u201371. https:\/\/doi.org\/10.1080\/14767058.2017.1383378.","journal-title":"J Maternal-Fetal Neonatal Med"},{"issue":"3","key":"1126_CR122","first-page":"321","volume":"13","author":"M Afshar","year":"2008","unstructured":"Afshar M, Golalipour MJ. Teratogenic effects of gabapentin on neural tube and limb development in mice. Neurosciences. 2008;13(3):321\u20133.","journal-title":"Neurosciences"},{"issue":"3","key":"1126_CR123","first-page":"239","volume":"14","author":"M Afshar","year":"2009","unstructured":"Afshar M, Hassanzadeh-Taheri MM, Moallem SA, et al. Teratogenic effects of gabapentin on the skeletal system of Balb\/C mice fetuses. Neurosciences. 2009;14(3):239\u201344.","journal-title":"Neurosciences"},{"issue":"1","key":"1126_CR124","first-page":"47","volume":"49","author":"Prakash","year":"2008","unstructured":"Prakash, Prabhu LV, Rai R, et al. Teratogenic effects of the anticonvulsant gabapentin in mice. Singap Med J. 2008;49(1):47\u201353.","journal-title":"Singap Med J"},{"issue":"6","key":"1126_CR125","doi-asserted-by":"publisher","first-page":"967","DOI":"10.5137\/1019-5149.JTN.34412-21.3","volume":"31","author":"A Cetinkal","year":"2021","unstructured":"Cetinkal A, Cakir A. Does gabapentin affect neural tube development? Experimental study using an early stage chick embryo model. Turk Neurosurg. 2021;31(6):967\u201372. https:\/\/doi.org\/10.5137\/1019-5149.JTN.34412-21.3.","journal-title":"Turk Neurosurg"},{"key":"1126_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.794544","volume":"9","author":"T Boggess","year":"2021","unstructured":"Boggess T, Williamson JC, Niebergall EB, et al. Alterations in Excitatory and Inhibitory Synaptic Development Within the Mesolimbic Dopamine Pathway in a Mouse Model of Prenatal Drug Exposure. Front Pediatr. 2021;9: 794544. https:\/\/doi.org\/10.3389\/fped.2021.794544.","journal-title":"Front Pediatr"},{"issue":"2","key":"1126_CR127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4149\/BLL_2017_022","volume":"118","author":"Z Erisgin","year":"2017","unstructured":"Erisgin Z, Tekelioglu Y. Flow cytometric examination of apoptotic effect on brain tissue in postnatal period created by intrauterine oxcarbazepine and gabapentin exposure. Bratisl Lek Listy. 2017;118(2):107\u201311. https:\/\/doi.org\/10.4149\/BLL_2017_022.","journal-title":"Bratisl Lek Listy"},{"issue":"9","key":"1126_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02387","volume":"5","author":"GM Badawy","year":"2019","unstructured":"Badawy GM, Atallah MN, Sakr SA. Effect of gabapentin on fetal rat brain and its amelioration by ginger. Heliyon. 2019;5(9): e02387. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02387.","journal-title":"Heliyon"},{"issue":"4","key":"1126_CR129","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14656566.2023.2165909","volume":"24","author":"HE Jones","year":"2023","unstructured":"Jones HE. How does a clinician approach the pharmacological management of opioid use disorders in pregnant women and pregnant people? Expert Opin Pharmacother. 2023;24(4):401\u20135.","journal-title":"Expert Opin Pharmacother"},{"key":"1126_CR130","doi-asserted-by":"publisher","unstructured":"Gambling L, Kennedy C, McArdle HJ. Iron and copper in fetal development. In: Semin. Cell Dev. Biol. 2011;22(6): 637-644. https:\/\/doi.org\/10.1016\/j.semcdb.2011.08.011","DOI":"10.1016\/j.semcdb.2011.08.011"},{"issue":"4\u20135","key":"1126_CR131","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.mam.2005.07.015","volume":"26","author":"JY Uriu-Adams","year":"2005","unstructured":"Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. Mol Aspects Med. 2005;26(4\u20135):268\u201398. https:\/\/doi.org\/10.1016\/j.mam.2005.07.015.","journal-title":"Mol Aspects Med"},{"issue":"2","key":"1126_CR132","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/HRP.0000000000000070","volume":"23","author":"J DeVido","year":"2015","unstructured":"DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015;23(2):112. https:\/\/doi.org\/10.1097\/HRP.0000000000000070.","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"1126_CR133","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/alcalc\/agz082","volume":"55","author":"B Rolland","year":"2020","unstructured":"Rolland B, Simon N, Franchitto N, et al. France grants an approval to baclofen for alcohol dependence. Alcohol Alcohol. 2020;55(1):44\u20135. https:\/\/doi.org\/10.1093\/alcalc\/agz082.","journal-title":"Alcohol Alcohol"},{"issue":"4","key":"1126_CR134","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/psychiatryint2040028","volume":"2","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Nix CA, Reed TD, et al. Pharmacologic and clinical considerations of nalmefene, a long duration opioid antagonist, in opioid overdose. Psychiatry Int. 2021;2(4):365\u201378. https:\/\/doi.org\/10.3390\/psychiatryint2040028.","journal-title":"Psychiatry Int"},{"key":"1126_CR135","unstructured":"European Medicines Agency. Selincro: nalmefene. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/selincro. Accessed 12 February 2024."},{"key":"1126_CR136","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Nalmefene. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548295\/. Accessed 27 Feb 2024."},{"key":"1126_CR137","unstructured":"Australian Government: Department of Health and Aged Care. Australian Public Assessment Report: Nalmefene (as hydrochloride dihydrate): 2016. Available from: https:\/\/www.tga.gov.au\/resources\/auspar\/auspar-nalmefene-hydrochloride-dihydrate. Accessed 12 February 2024."},{"key":"1126_CR138","unstructured":"Australian Government: Department of Health and Aged Care. SELINCRO nalmefene (as hydrochloride dihydrate) 18 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act. 2019. Available from: https:\/\/www.tga.gov.au\/resources\/cancellations-by-sponsors\/selincro-nalmefene-hydrochloride-dihydrate-18-mg-film-coated-tablet-blister-pack-cancelled-under-section-301c-act. Accessed 12 Feb 2024."},{"issue":"1","key":"1126_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100273","volume":"3","author":"T Guttuso","year":"2021","unstructured":"Guttuso T, Messing S, Tu X, et al. Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. Am J Obstet Gynecol MFM. 2021;3(1): 100273. https:\/\/doi.org\/10.1016\/j.ajogmf.2020.100273.","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"1","key":"1126_CR140","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41572-022-00406-1","volume":"8","author":"J MacKillop","year":"2022","unstructured":"MacKillop J, Agabio R, Feldstein Ewing SW, et al. Hazardous drinking and alcohol use disorders. Nat Rev Dis Primers. 2022;8(1):80. https:\/\/doi.org\/10.1038\/s41572-022-00406-1.","journal-title":"Nat Rev Dis Primers"},{"key":"1126_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015042.pub2","author":"S Minozzi","year":"2024","unstructured":"Minozzi S, Ambrosi L, Saulle R, et al. Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy. Cochrane Database Syst Rev. 2024. https:\/\/doi.org\/10.1002\/14651858.CD015042.pub2.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01126-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01126-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01126-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:15:57Z","timestamp":1735848957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01126-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01126-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"10 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.No funding was received for conducting this study. EQ, SR and DR are supported by an Australian Government Research Training Program Scholarship at The University of Western Australia. EK is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (No. 1172978).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts or\u00a0competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Supporting information can be found in the supplementary material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation was carried out by Ebony Quintrell and Erin Kelty; literature screening and analysis was performed by Ebony Quintrell, Danielle Russell and Sofa Rahmannia; supervision was performed by Erin Kelty, Caitlin S. Wyrwoll and Alexander Larcombe. The first draft of the manuscript was written by Ebony Quintrell and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}}]}}